GAMMA Investing LLC Increases Holdings in Bio-Rad Laboratories, Inc. $BIO

GAMMA Investing LLC lifted its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 20.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 734 shares of the medical research company’s stock after purchasing an additional 127 shares during the quarter. GAMMA Investing LLC’s holdings in Bio-Rad Laboratories were worth $177,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. First Pacific Advisors LP boosted its holdings in shares of Bio-Rad Laboratories by 136.0% in the first quarter. First Pacific Advisors LP now owns 372,555 shares of the medical research company’s stock valued at $90,739,000 after purchasing an additional 214,705 shares during the period. Ariel Investments LLC grew its position in Bio-Rad Laboratories by 29.3% during the 1st quarter. Ariel Investments LLC now owns 724,660 shares of the medical research company’s stock worth $176,498,000 after purchasing an additional 164,136 shares during the period. Dimensional Fund Advisors LP grew its position in Bio-Rad Laboratories by 17.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 877,040 shares of the medical research company’s stock worth $213,608,000 after purchasing an additional 130,921 shares during the period. Mawer Investment Management Ltd. boosted its stake in shares of Bio-Rad Laboratories by 14.8% during the 1st quarter. Mawer Investment Management Ltd. now owns 294,879 shares of the medical research company’s stock worth $71,821,000 after acquiring an additional 37,952 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Bio-Rad Laboratories by 45.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company’s stock worth $25,575,000 after acquiring an additional 32,874 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Friday, August 22nd. Royal Bank Of Canada lifted their price target on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a research note on Friday, August 1st. Wells Fargo & Company lifted their price objective on shares of Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an “equal weight” rating in a research note on Friday, August 1st. Finally, Zacks Research upgraded shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Three analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $333.50.

Bio-Rad Laboratories Price Performance

BIO opened at $269.95 on Tuesday. The company has a fifty day simple moving average of $278.55 and a 200 day simple moving average of $253.65. The firm has a market cap of $7.31 billion, a price-to-earnings ratio of 23.01 and a beta of 0.95. Bio-Rad Laboratories, Inc. has a twelve month low of $211.43 and a twelve month high of $387.99. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Thursday, July 31st. The medical research company reported $2.61 EPS for the quarter, beating analysts’ consensus estimates of $1.93 by $0.68. Bio-Rad Laboratories had a net margin of 12.50% and a return on equity of 4.01%. The firm had revenue of $651.60 million for the quarter, compared to the consensus estimate of $614.82 million. During the same period in the prior year, the firm posted $3.11 EPS. The firm’s revenue was up 2.1% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. Equities research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.